secwatch / observer
8-K filed May 2, 2024, 7:59 PM ET ticker PBSV CIK 0001304161
other material confidence high sentiment neutral materiality 0.30

Stockholders approve extension of long-term incentive plan to 2034; re-elect two directors

Pharma-Bio Serv, Inc.

Key facts

Extracted from this filing and checked against the source text.

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Pharma-Bio Serv, Inc. shareholders approved Approval of the Plan Amendment.

Proposal
equity plan
Outcome
passed
Exact text from the filing
The approval of the Plan Amendment received the following votes: Votes For Votes Against Abstain 7,523,008 5,127,032 3,854,521 There were 1,714,854 broker non-votes on this proposal.
View on SEC.gov
Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Pharma-Bio Serv, Inc. shareholders approved Election of Class II Directors.

Proposal
director election
Outcome
passed
Exact text from the filing
Kirk Michel and Dov Perlysky received the following votes: Nominee Votes For Votes Withheld Kirk Michel 12,647,540 3,857,021 Dov Perlysky 7,546,374 8,958,187 There were 1,714,854 broker non-votes on this proposal.
View on SEC.gov
Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Pharma-Bio Serv, Inc. shareholders approved Ratification of Crowe PR PSC as independent certified public accountants at the 2024-10-31 meeting.

Proposal
auditor ratification
Outcome
passed
Meeting
2024-10-31
Exact text from the filing
The ratification of the selection of Crowe PR PSC as the Company's independent certified public accountants for the fiscal year ending October 31, 2024 received the following votes: Votes For Votes Against Abstain 14,364,694 1,500 3,853,221 There were no broker non-votes on this proposal.
View on SEC.gov

1639 shareholder votes filed in the last 30 days. Browse all shareholder votes →

Pharma-Bio Serv, Inc. filing history →

Source: SEC EDGAR
accession 0001654954-24-005476
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.